ARTICLE | Emerging Company Profile
Through Aktis, MPM bets on radiotherapy for solid tumors
Emerging Company Profile: Aktis raises $72M A round to develop alpha-emitting radiotherapies with differentiated PK
March 18, 2021 11:43 PM UTC
Aktis believes the pharmacology of its solid tumor-targeting α-emitters will differentiate the MPM Capital-founded newco from the growing wave of targeted radiotherapy companies.
President and CEO Matthew Roden told BioCentury the company originated from MPM’s search for a technology that would be as transformative for solid tumors as CAR T cells have been for hematological cancers...